SaudiVax
SaudiVax is a Saudi Arabian biopharmaceutical company operating integrated R&D, GMP biomanufacturing, and SFDA-certified clinical and regulatory advisory services to localize vaccine and biologics production for Saudi Arabia, GCC, MENA, and OIC markets.
- Company typePrivate
- Founded2016
- HeadquartersThuwal, Saudi Arabia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SaudiVax does
SaudiVax (SVAX) is a Saudi Arabian biotechnology company founded in 2016 and headquartered in Thuwal, with operational facilities in Riyadh and Jeddah. It operates three integrated business units: SVAX Innovation (R&D for biologics and vaccines through proprietary and co-development products), SVAX Biomanufacturing (contract development and manufacturing services including a GMP-certified secondary packaging facility in Riyadh, an aseptic filling facility under construction, and a planned drug substances facility), and SVAX Advisory Business (an SFDA-certified CRO delivering clinical operations, regulatory affairs, and biomanufacturing training programs).
The company's technology stack centers on biologics and vaccine biomanufacturing, spanning cell line development, process optimization, aseptic fill-finish, and packaging using state-of-the-art equipment and software. Supporting capabilities include an SFDA-certified regulatory affairs function that helps local and international companies navigate Saudi product registration. SVAX pursues technology transfer and localization via partnerships with Henlius, PanGen Biotech, Boehringer Ingelheim Animal Health, and Bertis, covering both human biologics and animal health vaccines.
SVAX generates revenue across a diversified mix: CMO services for biologics and vaccines, CRO/clinical operations services, regulatory affairs advisory, professional biomanufacturing training, and licensing/distribution royalties for partner products across Saudi Arabia and MENA. Customer segments are enterprise biopharma companies (local and international), regional healthcare providers, and government/public health authorities aligned with Saudi Arabia's Vision 2030 and National Biotechnology Strategy to position the Kingdom as a biomanufacturing hub serving Saudi Arabia, GCC, and OIC countries.
SaudiVax firmographics
Firmographics- Name
- SaudiVax
- Legal name
- SaudiVax
- Website
- https://saudivax.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SaudiVax is a Saudi Arabian biopharmaceutical company operating integrated R&D, GMP biomanufacturing, and SFDA-certified clinical and regulatory advisory services to localize vaccine and biologics production for Saudi Arabia, GCC, MENA, and OIC markets.
- Ownership category
- akta.pro rank
SaudiVax industry classification
Industry- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
- akta.pro secondary industries
- Training & Competency Programs for GxP Compliance (HLAGAKAM), Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)
Keywords
Where SaudiVax is headquartered
LocationHeadquarters
- HQ city
- Thuwal
- HQ country
- Saudi Arabia
- HQ region
- Middle East
Offices2 records
Markets served
SaudiVax business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Organization (CMO) Services: Provides cutting-edge development and manufacturing services for biologics and vaccines. State-of-the-art facilities support projects from cell line development and process optimization to fill-finish and packaging, ensuring highest quality and regulatory compliance.
- Clinical Operations (CRO Services): SFDA-certified CRO providing end-to-end clinical trial services including study design, site selection, patient recruitment, and data management.
- Regulatory Affairs Services: Services to navigate SFDA requirements and streamline product registration for companies entering Saudi market.
- Biomanufacturing Training Programs: Specialized training programs aimed at building skilled workforce for Saudi Arabia's growing biotech industry, contributing to Vision 2030 objectives.
- Product Distribution Rights: Exclusive rights to register, market, and distribute partner products in Saudi Arabia and MENA countries, including technology transfer for local manufacturing.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
SaudiVax product offering
Product offeringCore offering
SaudiVax (SVAX) is an integrated biopharmaceutical company providing end-to-end services for vaccines and biologics across three business units: SVAX Innovation (R&D of proprietary and co-developed biologics), SVAX Biomanufacturing (GMP-certified contract development and manufacturing for cell line development, process optimization, aseptic fill-finish, and packaging), and SVAX Advisory Business (SFDA-certified clinical operations, regulatory affairs, and biomanufacturing training). The company serves local and international pharmaceutical and biotech firms seeking to access the Saudi and MENA markets.
Product overview
SaudiVax operates as an integrated biotechnology company offering three interconnected core business units: SVAX Innovation (R&D division for biologics and vaccines development with proprietary and co-development products), SVAX Biomanufacturing (contract development and manufacturing services including drug substance, fill-finish, and packaging facilities), and SVAX Advisory Business (SFDA-certified CRO providing clinical operations, regulatory affairs, and specialized training services). The company focuses on localizing biomanufacturing to achieve self-sufficiency in vaccines and biologics for Saudi Arabia, GCC, and OIC countries, aligned with Vision 2030.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Position Saudi Arabia as global leader in biomanufacturing achieving self-sufficiency and equitable access to vaccines and biologics
- +1 more outcomes
Companies that use SaudiVax
Customer profileSegments3 records
Ideal customer profiles3 records
SaudiVax technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SaudiVax partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core.
- Rubedo Life SciencescoreSVAX announced strategic partnership with Rubedo Life Sciences during FII Week in Riyadh. SVAX will support Rubedo's regulatory filings and conduct of Phase 2 clinical trials for lead program RLS-1496 in the Kingdom of Saudi Arabia and Dubai. Partnership builds Rubedo's footprint as a Hevolution portfolio company and reflects growing strategic importance of the region in healthy longevity research.
- Fakeeh Care GroupcoreSVAX and Fakeeh Care Group formed a mutually beneficial partnership built on both financial investment and strategic collaboration. Fakeeh Care Group made a strategic investment in SVAX, recognizing the company's potential to drive innovation in biopharmaceutical development and manufacturing. SVAX leverages Fakeeh's extensive network and expertise as a leading regional healthcare provider to advance R&D efforts and expand access to groundbreaking therapies.
- Shanghai Henlius Biotech Inc.coreSVAX and Henlius forged a strategic partnership to advance development, registration, and commercialization of innovative biopharmaceutical products in the MENAT region. Collaboration includes establishment of joint ventures focused on both commercialization and manufacturing within Saudi Arabia. Partnership aims to expand access to critical therapies and contribute to regional healthcare sector growth.
- Boehringer-Ingelheim Animal HealthcoreSVAX and Boehringer Ingelheim Animal Health partnership aimed at enhancing livestock protection and promoting animal health in Saudi Arabia. Collaboration revolves around three key pillars: local vaccine manufacturing, scientific collaboration, and pandemic preparedness.
- Sartorius AGcoreSVAX and Sartorius collaboration leverages Sartorius's wide range of technologies and subject matter experts to deliver the first Industrial Biomanufacturing Training program in the Middle East region, in partnership with King Abdulaziz University. Collaboration supports Saudi's ambition for biomanufacturing autonomy by building a sustainable biopharmaceuticals development and manufacturing ecosystem in alignment with Vision 2030.
- Bertis Inc.coreSVAX signed an exclusive agreement with Bertis Inc to localize proteomics-based testing in Oncology starting with breast cancer. Utilizing the MASTOCHECK platform technology for early detection of cancer, this innovative technology will be available in Saudi Arabia and the GCC.
- PanGen Biotech Inc.coreSVAX and PanGen Biotech entered an Exclusive Distribution Agreement granting SVAX exclusive rights to register, market, and distribute PanGen's biopharmaceutical products in Saudi Arabia and MENA countries. PanGen provides regulatory support and FDA-approved products while SVAX manages local regulatory approvals, marketing strategies, and sales forecasts. Collaboration includes technology transfer for local manufacturing.
- King Abdulaziz UniversitycoreSVAX partnered with King Abdulaziz University to create a specialized training program focused on development and localization of vaccines and biopharmaceuticals in Saudi Arabia. Program offers training through lectures, workshops, and hands-on experience, empowering Saudi youth with expertise needed for healthcare and biomanufacturing industries.
- Saudi Aramco (Namaat)coreSaudi Aramco and SVAX signed a Memorandum of Understanding to localize vaccine and biologics manufacturing in Saudi Arabia in line with Vision 2030. Saudi Aramco supports the initiative while SaudiVax focuses on developing and manufacturing. Collaboration aims to raise national awareness, attract investments, support funding applications, enhance vaccination programs, and position Saudi Arabia as a regional hub.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
SaudiVax competitors and assessment
Company assessmentDirect peers
- Syngene International: Syngene is an integrated CRO/CDMO offering discovery, development, and biologics manufacturing services. Comparable to SaudiVax's combined CRO/CMO plus R&D Innovation offering.
- WuXi Biologics: WuXi Biologics operates a global biologics discovery, development, and manufacturing platform (CDMO) similar to SaudiVax Biomanufacturing's CMO offering, including cell line development through fill-finish.
- PanGen Biotech: PanGen Biotech is a Korean biopharmaceutical company focused on biosimilars and biologics. It is SaudiVax's exclusive distribution partner for Saudi Arabia and MENA, making it the closest distribution-side peer.
- Shanghai Henlius Biotech: Henlius is a Chinese biopharmaceutical company developing, manufacturing, and commercializing biosimilars and innovative mAbs. It is SaudiVax's direct JV partner for the FosunHenlius Middle East United Company, operating in the same biologics manufacturing + MENA commercialization space.
- Aragen Life Sciences: Aragen (formerly GVK BIO) is a global CRO/CDMO with biologics development and manufacturing capabilities, comparable to SaudiVax's CMO and Advisory business lines.
- Samsung Biologics: Samsung Biologics is a leading global CDMO offering biologics manufacturing, fill-finish, and process development. Highly comparable to SaudiVax's CMO/biomanufacturing business line for biologics and vaccines.
Regional players
- Gulf Pharmaceutical Industries (Julphar): Julphar is a leading MENA-based pharmaceutical manufacturer with biologics and vaccine capabilities. A regional analog serving GCC markets for locally manufactured biologics and pharmaceuticals.
- SPIMACO Addwaeih: SPIMACO is a major Saudi pharmaceutical company manufacturing and marketing medicines locally. Comparable as a Saudi-based drug manufacturer operating under SFDA regulations, though focused on small molecules rather than biologics.
Broad incumbents
- Catalent: Catalent is a global large-scale CDMO offering biologics and sterile fill-finish services. Comparable to SaudiVax's planned aseptic filling and biologics manufacturing capabilities, although with much broader geographic reach.
- Lonza Group: Lonza is one of the world's largest CDMOs serving biologics, cell and gene therapy, and small molecules. Comparable across SaudiVax's full biologics CMO stack from cell line to fill-finish.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SaudiVax social profiles
Digital presenceSaudiVax compliance and trust
Trust signalCompliance1 record
SaudiVax financial estimates
Financial estimateRevenue estimate
Valuation estimate
SaudiVax leadership team
Management profileNumber of profiles
SaudiVax funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SaudiVax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SaudiVax
What does SaudiVax do?
SaudiVax (SVAX) is an integrated biopharmaceutical company providing end-to-end services for vaccines and biologics across three business units: SVAX Innovation (R&D of proprietary and co-developed biologics), SVAX Biomanufacturing (GMP-certified contract development and manufacturing for cell line development, process optimization, aseptic fill-finish, and packaging), and SVAX Advisory Business (SFDA-certified clinical operations, regulatory affairs, and biomanufacturing training). The company serves local and international pharmaceutical and biotech firms seeking to access the Saudi and MENA markets.
Is SaudiVax a public or private company?
SaudiVax is a private company. It is currently operating.
When was SaudiVax founded?
SaudiVax was founded in 2016. It employs 11 to 50 people.
Where is SaudiVax based?
SaudiVax is headquartered in Thuwal, Saudi Arabia, in the Middle East region.
How does SaudiVax make money?
Five revenue lines are on record. Contract Manufacturing Organization (CMO) Services are the primary driver. The others are clinical Operations (CRO Services), regulatory Affairs Services, biomanufacturing Training Programs and product Distribution Rights.
Who are SaudiVax's main competitors?
Direct peers on record are Syngene International, WuXi Biologics, PanGen Biotech, Shanghai Henlius Biotech, Aragen Life Sciences and Samsung Biologics. Regional players are Gulf Pharmaceutical Industries (Julphar) and SPIMACO Addwaeih. Broad incumbents are Catalent and Lonza Group.
Does SaudiVax have an API?
No public API is recorded for SaudiVax.
What industry is SaudiVax in?
Its primary akta.pro industry code is HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight), with a secondary code of HLAGAKAM, Training & Competency Programs for GxP Compliance. Its NAICS code is 54171 and its SIC code is 8071.